Developer docs
API playgroundTry for free, no card

Search company profiles

Duchesnay

Full company profile

uuid000cxfa

Namestring
Duchesnay
Legal namestring
Duchesnay Inc.
Websiteurl
duchesnay.com
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Duchesnay Inc. is a Canadian specialty pharmaceutical company headquartered in Blainville, Quebec, that develops and commercializes prescription pharmaceutical products and medical devices primarily for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis. Founded in 1970 and re-oriented toward women's health in 1992 following a family member's difficult pregnancy, it became the first pharmaceutical company in Canada dedicated specifically to that therapeutic area. Its portfolio spans proprietary formulations including delayed-release tablets (Diclectin for nausea and vomiting of pregnancy), modified-release capsules (Mictoryl for urology), the novel PrRingza year-long reusable contraceptive vaginal ring co-developed with the Population Council, and oral contraceptives (Slynd), all manufactured at a Quebec facility that has tripled capacity since 2021.

The company operates as part of Duchesnay Pharmaceutical Group, a six-company private structure that also includes Duchesnay USA, Medunik Canada/USA (rare diseases), and Analog Pharma Canada (affordable generics, founded January 2024). Duchesnay distributes primarily through Canadian pharmacies reimbursed via public drug plans and private insurance, deploys field sales representatives targeting OB/GYNs and primary care prescribers, runs a toll-free medical information service, and exports to more than 50 countries. Following a June 2021 management buyout, the Group has doubled its workforce, expanded exports tenfold, launched new products including PrALOG and PrRingza, signed a license with Mochida Pharmaceutical for the Japanese market, and been selected for the Government of Canada's Global Hypergrowth Project.

Short descriptiontext

Duchesnay is a Canadian specialty pharmaceutical company developing and manufacturing prescription drugs and medical devices for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis, serving Canadian patients and exporting to over 50 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBlainville, Canada
HQ citystring
Blainville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health pharmaceuticals, specialty prescription drugs, prenatal care medications, contraceptive pharmaceutical products, menopause therapeutics
Industry4 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYHSABALAL
Compounding & Customized Medication Management Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmacies and Drug Retailers45611
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Women's Health Pharmaceuticals
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Pharmaceutical Products
TypeOne Time License
Description

Duchesnay generates revenue primarily through the sale of prescription pharmaceutical products in Canada, including Diclectin® for nausea and vomiting of pregnancy, Osphena® for menopause symptoms, Slynd® for contraception, Mictoryl® for urology, and other therapeutic products. Revenue flows through pharmacy dispensaries reimbursed by public drug plans and private insurance.

duchesnay.com
2Generic Medications (Analog Pharma Canada)
TypeOne Time License
Description

Through its subsidiary Analog Pharma Canada (founded January 2024), Duchesnay sells affordable generic versions of its own branded drugs, including PrALOG-Doxylamine/Pyridoxine™ as a generic of PrDiclectin®, diversifying revenue into the generic pharmaceutical market.

newswire.ca
3International Licensing and Partnerships
TypeLicensing Royalties
Description

Duchesnay generates revenue through licensing agreements for its proprietary products in international markets, such as the partnership with Mochida Pharmaceutical Co., Ltd. to bring Bonjesta® to Japan, with anticipated product launch by 2030.

newswire.ca
4Manufacturing and Export
TypeHardware Sales
Description

With a state-of-the-art manufacturing plant in Quebec, Duchesnay exports pharmaceutical products to more than 50 countries, representing significant international revenue generation.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Prescription pharmaceutical products — price determined by public formulary and private insurance reimbursement
ModelOtherBilling cadenceOther
Notes

Prescription drugs are reimbursed through public drug plans and private insurance. Specific price points are not publicly listed. Patient assistance programs such as RxHelp™ ONE may provide access support.

duchesnay.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Diclectin
Description

Doxylamine succinate (10 mg) pyridoxine hydrochloride (10 mg) delayed release tablet for nausea and vomiting of pregnancy

duchesnay.com
+9 more records
Core offering1 text field

Duchesnay is a Canadian specialty pharmaceutical company that develops, manufactures, and distributes prescription medications and medical devices primarily for women's health across the full life continuum, from pregnancy through menopause. Its portfolio covers nausea and vomiting of pregnancy, contraception, dyspareunia, bacterial vaginosis, overactive bladder, prenatal nutrition, and proctology. Products are manufactured domestically in Quebec and distributed through Canadian pharmacies with reimbursement from public and private drug plans, while international expansion is delivered through licensing partnerships and exports to more than 50 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Tripled annual tablet production capacity since 2021, enabling greater domestic supply resilience
+3 more records
Product overview1 text field

Duchesnay is a Canadian specialty pharmaceutical company that offers a portfolio of prescription pharmaceutical products and medical devices for women's health and related therapeutic areas. The product portfolio spans obstetrics and gynecology (Diclectin®, Osphena®), contraception (Ringza™, Slynd®), proctology (Proctofoam-HC®), urology (Mictoryl® product line), vitamin-mineral supplements for prenatal/postpartum use (PregVit®, Pregvit folic 5®), and bacterial vaginosis treatment (Vablys®). The company also manufactures generic medications through its subsidiary Analog Pharma Canada. Products are manufactured primarily in Canada with some imported ingredients, and certain products carry Kosher-Halal certifications.

Product and service14 records
1Diclectin®
CategoryPrescription pharmaceutical product
Description

Doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) delayed-release tablet indicated for nausea and vomiting of pregnancy. Kosher-Halal certified and manufactured in Canada. Distributed through Canadian pharmacies and reimbursed through public and private drug plans.

2Osphena®
CategoryPrescription pharmaceutical product
Description

Ospemifene tablets 60 mg indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Targeted at postmenopausal women and prescribed by OB/GYNs and primary care physicians.

3Slynd®
CategoryPrescription pharmaceutical product
Description

Drospirenone tablets 4 mg, a progestin-only oral contraceptive pill indicated for contraception in women. Targeted at women seeking estrogen-free contraception and prescribed by OB/GYNs and primary care physicians.

4Ringza™ (PrRingza™)
CategoryMedical device product
Description

Segesterone acetate and ethinylestradiol vaginal system delivering 0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day. A reusable silicone ring providing up to one year of contraception. Co-developed with the Population Council; Canada was the first country to introduce this product globally.

5Mictoryl® Pediatric 5 mg
CategoryPrescription pharmaceutical product
Description

Propiverine hydrochloride tablets 5 mg for pediatric urology conditions, including overactive bladder. Prescribed by urologists and primary care physicians.

6Mictoryl® 30 mg
CategoryPrescription pharmaceutical product
Description

Propiverine hydrochloride modified-release capsules 30 mg for urology indications including overactive bladder. Prescribed by urologists.

7Mictoryl® 45 mg
CategoryPrescription pharmaceutical product
Description

Propiverine hydrochloride modified-release capsules 45 mg for urology indications including overactive bladder. Prescribed by urologists.

8PregVit®
CategoryVitamin-mineral supplement
Description

Vitamin-mineral supplement tablets for prenatal and postpartum use. Kosher-Halal certified and manufactured in Canada. Used by pregnant and breastfeeding women for nutritional support.

9Pregvit folic 5®
CategoryVitamin-mineral supplement
Description

Vitamin-mineral supplement tablets with high-dose folic acid (5 mg) for prenatal use. Kosher-Halal certified and manufactured in Canada. Indicated for women requiring elevated folic acid intake during pregnancy.

10Proctofoam-HC®
CategoryPrescription pharmaceutical product
Description

Hydrocortisone acetate and pramoxine hydrochloride aerosol foam for proctology indications. Used for the symptomatic relief of anorectal disorders and prescribed by primary care physicians and colorectal specialists. Currently experiencing drug shortage per source data.

11Prevegyne®
CategoryMedical device product
Description

Vitamin C (ascorbic acid) 250 mg controlled-release vaginal tablet. Listed in source data as no longer available in Canada.

12Vablys®
CategoryPrescription pharmaceutical product
Description

Dequalinium chloride tablets 10 mg indicated for the treatment of bacterial vaginosis. Prescribed by OB/GYNs and primary care physicians for adult women.

13Bonjesta®
CategoryPrescription pharmaceutical product
Description

Doxylamine succinate and pyridoxine combination product licensed to Mochida Pharmaceutical Co., Ltd. for the Japanese market. Intended to address the lack of approved nausea and vomiting of pregnancy treatments in Japan, with anticipated product launch by 2030.

14PrALOG-Doxylamine/Pyridoxine™
CategoryGeneric prescription pharmaceutical product
Description

Affordable generic version of PrDiclectin® (doxylamine succinate and pyridoxine) for managing nausea and vomiting of pregnancy, sold through Analog Pharma Canada, a wholly-owned subsidiary of Duchesnay Pharmaceutical Group. First product launched by Analog Pharma Canada in 2025; manufactured in Quebec.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierModerateTypeGTM or Marketing PartnerAnnounced on2026-04-22
Description

Duchesnay and PeriPharm jointly published a research article in the Journal of Obstetrics and Gynaecology of Canada revealing significant gaps in women's health medication access in Canada, based on a 20-year analysis (2003–2023). Duchesnay provided financial support for the PeriPharm study, and the findings were presented at the Femtech Canada Forum. The companies are using these findings to advocate for regulatory and reimbursement policy reforms to improve access to innovative therapies for Canadian women.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

The Population Council (New York-based) collaborated with Duchesnay to develop PrRingza™, a contraceptive vaginal system releasing segesterone acetate and ethinylestradiol, reusable for up to one year. Duchesnay launched the product in Canada as the first country globally. The Council's scientific expertise in contraceptive development combined with Duchesnay's regulatory and commercial capabilities in women's health made this co-development possible. The partnership was also extended to develop a potential new treatment for multiple sclerosis.

3Mochida Pharmaceutical Co., Ltd.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-15
Description

Duchesnay Inc. and Mochida Pharmaceutical Co., Ltd. signed a license agreement to bring Bonjesta® (doxylamine succinate/pyridoxine) to the Japanese market, addressing the lack of approved treatments for nausea and vomiting of pregnancy in Japan. Mochida will conduct research and seek regulatory approval, with a product launch targeted for 2030. This partnership represents a strategic milestone for Duchesnay's international expansion, as quoted by VP Suzanne Paszkiewicz in Les Affaires.

newswire.ca
Strategic tierCoreTypeOthers
Description

Duchesnay Pharmaceutical Group (DPG) was selected as one of only eight companies across Canada for the Government of Canada's Global Hypergrowth Project, receiving exclusive and personalized support for at least two years to accelerate growth into an anchor firm in the Canadian economy. This recognition confers strategic government support and access to growth resources.

5Analog Pharma Canada
Strategic tierCoreTypeOthers
Description

Analog Pharma Canada is a pharmaceutical company founded in January 2024 and wholly part of Duchesnay Pharmaceutical Group. It launched its first product — PrALOG-Doxylamine/Pyridoxine™, a generic version of DPG's flagship PrDiclectin® — leveraging the Group's manufacturing capabilities and maternal health expertise. Its mandate is to build a portfolio of high-quality, affordable generic medications targeting orphan drugs and Duchesnay-owned products, supporting a self-sustainable Canadian healthcare supply chain.

newswire.ca
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global specialty pharmaceutical company focused exclusively on women's health, covering contraception, fertility, menopause, and related therapeutic areas. Directly comparable as a women's-health-only specialty pharma with branded prescription products distributed internationally.

TypeBroad incumbent
Description

Large global women's health-focused pharmaceutical company spun out of Merck, offering prescription therapies across contraception, fertility, and menopause. Comparable as a broader women's health incumbent whose portfolio overlaps Duchesnay's core therapeutic categories.

TypeDirect peer
Description

Specialty pharmaceutical division focused on women's health, maternal health, and reproductive care across multiple geographies. Closely comparable as a women's health specialty pharma leveraging partnerships and licensing to extend global reach.

TypeBroad incumbent
Description

Major pharmaceutical company with a substantial women's health portfolio spanning contraception (Mirena, Yaz), menopause, and gynecological therapies. Comparable as a broad incumbent whose franchise products compete in the same therapy areas where Duchesnay operates.

TypeEmerging player
Description

Women's health specialty pharma focused on contraception, with branded hormonal contraceptive products brought to market through partnerships. Comparable as an emerging women's-health specialist pursuing similar regulatory and commercialization pathways.

6Padagis (formerly TherapeuticsMD women's health portfolio)
TypeBroad incumbent
Description

Specialty pharmaceutical company with a significant women's health portfolio in contraception, menopause, and prenatal care in North America. Comparable as a North American-focused women's health branded and generics player.

TypeEmerging player
Description

Global pharmaceutical company with a growing women's health segment including hormonal contraceptives and prenatal supplements. Comparable in product categories such as prenatal vitamins and hormonal contraception, with broader geographic reach.

TypeBroad incumbent
Description

Large diversified pharmaceutical company with a women's health portfolio that includes contraception (Lo Loestrin), menopause therapy, and gynecological products. Comparable as a broad incumbent competing in the same prescriber channels.

TypeEmerging player
Description

Specialty and generics pharmaceutical company with women's health offerings including hormonal contraceptives and prenatal supplements. Comparable through its generic/specialty mix and overlap in prenatal and contraceptive categories.

TypeBroad incumbent
Description

Specialty pharmaceutical company with branded and generic women's health products, including contraceptives and menopause therapies. Comparable as a North American-focused women's health specialty/generics player with similar product mix.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Duchesnay

Women's Health Pharmaceuticalsduchesnay.com

Duchesnay is a Canadian specialty pharmaceutical company developing and manufacturing prescription drugs and medical devices for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis, serving Canadian patients and exporting to over 50 countries.

What Duchesnay does

Duchesnay Inc. is a Canadian specialty pharmaceutical company headquartered in Blainville, Quebec, that develops and commercializes prescription pharmaceutical products and medical devices primarily for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis. Founded in 1970 and re-oriented toward women's health in 1992 following a family member's difficult pregnancy, it became the first pharmaceutical company in Canada dedicated specifically to that therapeutic area. Its portfolio spans proprietary formulations including delayed-release tablets (Diclectin for nausea and vomiting of pregnancy), modified-release capsules (Mictoryl for urology), the novel PrRingza year-long reusable contraceptive vaginal ring co-developed with the Population Council, and oral contraceptives (Slynd), all manufactured at a Quebec facility that has tripled capacity since 2021.

The company operates as part of Duchesnay Pharmaceutical Group, a six-company private structure that also includes Duchesnay USA, Medunik Canada/USA (rare diseases), and Analog Pharma Canada (affordable generics, founded January 2024). Duchesnay distributes primarily through Canadian pharmacies reimbursed via public drug plans and private insurance, deploys field sales representatives targeting OB/GYNs and primary care prescribers, runs a toll-free medical information service, and exports to more than 50 countries. Following a June 2021 management buyout, the Group has doubled its workforce, expanded exports tenfold, launched new products including PrALOG and PrRingza, signed a license with Mochida Pharmaceutical for the Japanese market, and been selected for the Government of Canada's Global Hypergrowth Project.

Duchesnay firmographics

Firmographics
Name
Duchesnay
Legal name
Duchesnay Inc.
Website
https://duchesnay.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
51–100 employees
Short description
Duchesnay is a Canadian specialty pharmaceutical company developing and manufacturing prescription drugs and medical devices for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis, serving Canadian patients and exporting to over 50 countries.
Ownership category
akta.pro rank

Duchesnay industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmacies and Drug Retailers (45611)
SIC
Pharmaceutical Preparations (2834), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYHSABALAL
Compounding & Customized Medication Management Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support

Keywords

  • Women's health pharmaceuticals
  • Specialty prescription drugs
  • Prenatal care medications
  • Contraceptive pharmaceutical products
  • Menopause therapeutics

Where Duchesnay is headquartered

Location

Headquarters

HQ city
Blainville
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Duchesnay business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Prescription Pharmaceutical Products: Duchesnay generates revenue primarily through the sale of prescription pharmaceutical products in Canada, including Diclectin® for nausea and vomiting of pregnancy, Osphena® for menopause symptoms, Slynd® for contraception, Mictoryl® for urology, and other therapeutic products. Revenue flows through pharmacy dispensaries reimbursed by public drug plans and private insurance.
  2. Generic Medications (Analog Pharma Canada): Through its subsidiary Analog Pharma Canada (founded January 2024), Duchesnay sells affordable generic versions of its own branded drugs, including PrALOG-Doxylamine/Pyridoxine™ as a generic of PrDiclectin®, diversifying revenue into the generic pharmaceutical market.
  3. International Licensing and Partnerships: Duchesnay generates revenue through licensing agreements for its proprietary products in international markets, such as the partnership with Mochida Pharmaceutical Co., Ltd. to bring Bonjesta® to Japan, with anticipated product launch by 2030.
  4. Manufacturing and Export: With a state-of-the-art manufacturing plant in Quebec, Duchesnay exports pharmaceutical products to more than 50 countries, representing significant international revenue generation.

Pricing tiers

ModelBillingPrice
OtherOtherPrescription pharmaceutical products — price determined by public formulary and private insurance reimbursement

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Duchesnay product offering

Product offering

Core offering

Duchesnay is a Canadian specialty pharmaceutical company that develops, manufactures, and distributes prescription medications and medical devices primarily for women's health across the full life continuum, from pregnancy through menopause. Its portfolio covers nausea and vomiting of pregnancy, contraception, dyspareunia, bacterial vaginosis, overactive bladder, prenatal nutrition, and proctology. Products are manufactured domestically in Quebec and distributed through Canadian pharmacies with reimbursement from public and private drug plans, while international expansion is delivered through licensing partnerships and exports to more than 50 countries.

Product overview

Duchesnay is a Canadian specialty pharmaceutical company that offers a portfolio of prescription pharmaceutical products and medical devices for women's health and related therapeutic areas. The product portfolio spans obstetrics and gynecology (Diclectin®, Osphena®), contraception (Ringza™, Slynd®), proctology (Proctofoam-HC®), urology (Mictoryl® product line), vitamin-mineral supplements for prenatal/postpartum use (PregVit®, Pregvit folic 5®), and bacterial vaginosis treatment (Vablys®). The company also manufactures generic medications through its subsidiary Analog Pharma Canada. Products are manufactured primarily in Canada with some imported ingredients, and certain products carry Kosher-Halal certifications.

Differentiator

Problem solved

Functional benefit

Brands

  • Diclectin: Doxylamine succinate (10 mg) pyridoxine hydrochloride (10 mg) delayed release tablet for nausea and vomiting of pregnancy
  • PregVit
  • Pregvit folic 5
  • Mictoryl
  • Osphena
  • Ringza
  • Slynd
  • Vablys
  • Proctofoam-HC
  • Prevegyne

Products and services

  • Diclectin® Doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) delayed-release tablet indicated for nausea and vomiting of pregnancy. Kosher-Halal certified and manufactured in Canada. Distributed through Canadian pharmacies and reimbursed through public and private drug plans.
  • Osphena® Ospemifene tablets 60 mg indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Targeted at postmenopausal women and prescribed by OB/GYNs and primary care physicians.
  • Slynd® Drospirenone tablets 4 mg, a progestin-only oral contraceptive pill indicated for contraception in women. Targeted at women seeking estrogen-free contraception and prescribed by OB/GYNs and primary care physicians.
  • Ringza™ (PrRingza™) Segesterone acetate and ethinylestradiol vaginal system delivering 0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day. A reusable silicone ring providing up to one year of contraception. Co-developed with the Population Council; Canada was the first country to introduce this product globally.
  • Mictoryl® Pediatric 5 mg Propiverine hydrochloride tablets 5 mg for pediatric urology conditions, including overactive bladder. Prescribed by urologists and primary care physicians.
  • Mictoryl® 30 mg Propiverine hydrochloride modified-release capsules 30 mg for urology indications including overactive bladder. Prescribed by urologists.
  • Mictoryl® 45 mg Propiverine hydrochloride modified-release capsules 45 mg for urology indications including overactive bladder. Prescribed by urologists.
  • PregVit® Vitamin-mineral supplement tablets for prenatal and postpartum use. Kosher-Halal certified and manufactured in Canada. Used by pregnant and breastfeeding women for nutritional support.
  • Pregvit folic 5® Vitamin-mineral supplement tablets with high-dose folic acid (5 mg) for prenatal use. Kosher-Halal certified and manufactured in Canada. Indicated for women requiring elevated folic acid intake during pregnancy.
  • Proctofoam-HC® Hydrocortisone acetate and pramoxine hydrochloride aerosol foam for proctology indications. Used for the symptomatic relief of anorectal disorders and prescribed by primary care physicians and colorectal specialists. Currently experiencing drug shortage per source data.
  • Prevegyne® Vitamin C (ascorbic acid) 250 mg controlled-release vaginal tablet. Listed in source data as no longer available in Canada.
  • Vablys® Dequalinium chloride tablets 10 mg indicated for the treatment of bacterial vaginosis. Prescribed by OB/GYNs and primary care physicians for adult women.
  • Bonjesta® Doxylamine succinate and pyridoxine combination product licensed to Mochida Pharmaceutical Co., Ltd. for the Japanese market. Intended to address the lack of approved nausea and vomiting of pregnancy treatments in Japan, with anticipated product launch by 2030.
  • PrALOG-Doxylamine/Pyridoxine™ Affordable generic version of PrDiclectin® (doxylamine succinate and pyridoxine) for managing nausea and vomiting of pregnancy, sold through Analog Pharma Canada, a wholly-owned subsidiary of Duchesnay Pharmaceutical Group. First product launched by Analog Pharma Canada in 2025; manufactured in Quebec.

Quantifiable outcome

  • Tripled annual tablet production capacity since 2021, enabling greater domestic supply resilience
  • +3 more outcomes

Companies that use Duchesnay

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Duchesnay technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Duchesnay partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered moderate and core.

  • PeriPharmmoderateGTM or Marketing Partner · 22 April 2026Duchesnay and PeriPharm jointly published a research article in the Journal of Obstetrics and Gynaecology of Canada revealing significant gaps in women's health medication access in Canada, based on a 20-year analysis (2003–2023). Duchesnay provided financial support for the PeriPharm study, and the findings were presented at the Femtech Canada Forum. The companies are using these findings to advocate for regulatory and reimbursement policy reforms to improve access to innovative therapies for Canadian women.
  • Population CouncilcoreStrategic or Co-development Partner · 7 April 2026The Population Council (New York-based) collaborated with Duchesnay to develop PrRingza™, a contraceptive vaginal system releasing segesterone acetate and ethinylestradiol, reusable for up to one year. Duchesnay launched the product in Canada as the first country globally. The Council's scientific expertise in contraceptive development combined with Duchesnay's regulatory and commercial capabilities in women's health made this co-development possible. The partnership was also extended to develop a potential new treatment for multiple sclerosis.
  • Mochida Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 15 December 2025Duchesnay Inc. and Mochida Pharmaceutical Co., Ltd. signed a license agreement to bring Bonjesta® (doxylamine succinate/pyridoxine) to the Japanese market, addressing the lack of approved treatments for nausea and vomiting of pregnancy in Japan. Mochida will conduct research and seek regulatory approval, with a product launch targeted for 2030. This partnership represents a strategic milestone for Duchesnay's international expansion, as quoted by VP Suzanne Paszkiewicz in Les Affaires.
  • Government of Canada (Global Hypergrowth Project)coreOthersDuchesnay Pharmaceutical Group (DPG) was selected as one of only eight companies across Canada for the Government of Canada's Global Hypergrowth Project, receiving exclusive and personalized support for at least two years to accelerate growth into an anchor firm in the Canadian economy. This recognition confers strategic government support and access to growth resources.
  • Analog Pharma CanadacoreOthersAnalog Pharma Canada is a pharmaceutical company founded in January 2024 and wholly part of Duchesnay Pharmaceutical Group. It launched its first product — PrALOG-Doxylamine/Pyridoxine™, a generic version of DPG's flagship PrDiclectin® — leveraging the Group's manufacturing capabilities and maternal health expertise. Its mandate is to build a portfolio of high-quality, affordable generic medications targeting orphan drugs and Duchesnay-owned products, supporting a self-sustainable Canadian healthcare supply chain.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Duchesnay competitors and assessment

Company assessment

Direct peers

  • Theramex: Global specialty pharmaceutical company focused exclusively on women's health, covering contraception, fertility, menopause, and related therapeutic areas. Directly comparable as a women's-health-only specialty pharma with branded prescription products distributed internationally.
  • Exeltis: Specialty pharmaceutical division focused on women's health, maternal health, and reproductive care across multiple geographies. Closely comparable as a women's health specialty pharma leveraging partnerships and licensing to extend global reach.

Broad incumbents

  • Organon: Large global women's health-focused pharmaceutical company spun out of Merck, offering prescription therapies across contraception, fertility, and menopause. Comparable as a broader women's health incumbent whose portfolio overlaps Duchesnay's core therapeutic categories.
  • Bayer (Women's Health / Pharma): Major pharmaceutical company with a substantial women's health portfolio spanning contraception (Mirena, Yaz), menopause, and gynecological therapies. Comparable as a broad incumbent whose franchise products compete in the same therapy areas where Duchesnay operates.
  • Padagis (formerly TherapeuticsMD women's health portfolio): Specialty pharmaceutical company with a significant women's health portfolio in contraception, menopause, and prenatal care in North America. Comparable as a North American-focused women's health branded and generics player.
  • AbbVie: Large diversified pharmaceutical company with a women's health portfolio that includes contraception (Lo Loestrin), menopause therapy, and gynecological products. Comparable as a broad incumbent competing in the same prescriber channels.
  • Endo International: Specialty pharmaceutical company with branded and generic women's health products, including contraceptives and menopause therapies. Comparable as a North American-focused women's health specialty/generics player with similar product mix.

Emerging players

  • Agile Therapeutics: Women's health specialty pharma focused on contraception, with branded hormonal contraceptive products brought to market through partnerships. Comparable as an emerging women's-health specialist pursuing similar regulatory and commercialization pathways.
  • Lupin Pharmaceuticals (Women's Health): Global pharmaceutical company with a growing women's health segment including hormonal contraceptives and prenatal supplements. Comparable in product categories such as prenatal vitamins and hormonal contraception, with broader geographic reach.
  • Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with women's health offerings including hormonal contraceptives and prenatal supplements. Comparable through its generic/specialty mix and overlap in prenatal and contraceptive categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Duchesnay social profiles

Digital presence

Duchesnay financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Duchesnay leadership team

Management profile

Number of profiles

Profiles2 records

Duchesnay subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Duchesnay funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Duchesnay M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Duchesnay

What does Duchesnay do?

Duchesnay is a Canadian specialty pharmaceutical company that develops, manufactures, and distributes prescription medications and medical devices primarily for women's health across the full life continuum, from pregnancy through menopause. Its portfolio covers nausea and vomiting of pregnancy, contraception, dyspareunia, bacterial vaginosis, overactive bladder, prenatal nutrition, and proctology. Products are manufactured domestically in Quebec and distributed through Canadian pharmacies with reimbursement from public and private drug plans, while international expansion is delivered through licensing partnerships and exports to more than 50 countries.

Is Duchesnay a public or private company?

Duchesnay is a private company. It is classified as management employee owned and is currently operating.

When was Duchesnay founded?

Duchesnay was founded in 1970. It employs 51 to 100 people.

Where is Duchesnay based?

Duchesnay is headquartered in Blainville, Canada, in the North America region.

How does Duchesnay make money?

Four revenue lines are on record. Prescription Pharmaceutical Products are the primary driver. The others are generic Medications (Analog Pharma Canada), international Licensing and Partnerships and manufacturing and Export.

Who are Duchesnay's main competitors?

Direct peers on record are Theramex and Exeltis. Broad incumbents are Organon, Bayer (Women's Health / Pharma), Padagis (formerly TherapeuticsMD women's health portfolio), AbbVie and Endo International. Emerging players are Agile Therapeutics, Lupin Pharmaceuticals (Women's Health) and Amneal Pharmaceuticals.

Does Duchesnay have an API?

No public API is recorded for Duchesnay.

What industry is Duchesnay in?

Duchesnay's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireFive years after its acquisition by senior management, Duchesnay Pharmaceutical Group continues to grow as one of Canada's few full-range pharma businessesDuchesnay Pharmaceutical Group celebrated five years since its 2021 buyout by senior management, citing sustained growth in sales, exports, and employment. The group now exports to over 45 countries, with a target of 60 within two years, and has added a sixth company to its portfolio.PR NewswireDuchesnay and PeriPharm emphasize the need to update regulatory and reimbursement policies to improve access to innovations in women's healthDuchesnay and PeriPharm published an article in the Journal of Obstetrics and Gynaecology of Canada revealing significant gaps in women's health medication access in Canada, based on a 20-year analysis from 2003 to 2023. The study found that Canadian women wait more than three years on average for newly approved women's health medications to appear on public formularies, approximately one year longer than the delay for other medications, with fewer than two-thirds ultimately reimbursed through public drug plans. The companies are using these findings to advocate for regulatory and reimbursement policy reforms to improve timely access to innovative therapies for Canadian women.NewswireDuchesnay and PeriPharm emphasize the need to update regulatory and reimbursement policies to improve access to innovations in women's healthDuchesnay and PeriPharm published a study in the Journal of Obstetrics and Gynaecology Canada showing Canadian women wait over three years for women's health medications. Of 45 FDA-approved women's health drugs from 2003-2023, only 24 were approved in Canada, and fewer than two-thirds are reimbursed by public plans.BioSpaceDuchesnay and PeriPharm emphasize the need to update regulatory and reimbursement policies to improve access to innovations in women’s healthDuchesnay and PeriPharm published a study in the Journal of Obstetrics and Gynaecology Canada on barriers to women's health innovations. The analysis of 20 years of data found that only 24 of 45 FDA-approved women's health medications were approved in Canada, and it takes over three years for a new drug to appear on a public formulary. The authors call for updated regulatory and reimbursement policies to improve access.PR NewswireDuchesnay launches a contraceptive vaginal system that can be used for up to a full yearDuchesnay, a Canadian specialty pharmaceutical company, announced the launch of PrRingzaTM, a new contraceptive vaginal system in Canada, making it the first country to introduce the product globally. The device, developed in collaboration with the Population Council, is a reusable silicone ring offering up to one year of contraception with only one pharmacy visit per year, delivering segesterone acetate and ethinyl estradiol. The product represents Duchesnay's expansion into contraception and reinforces the company's commitment to advancing women's health solutions.NewswireDuchesnay launches a contraceptive vaginal system that can be used for up to a full yearDuchesnay, a Canadian specialty pharmaceutical company, announced the launch of PrRingzaTM, a contraceptive vaginal system developed in collaboration with the Population Council, making Canada the first country to introduce this product. The silicone ring releases segesterone acetate and ethinyl estradiol daily and is designed for reuse for up to one year, requiring only a single pharmacy visit annually. The efficacy and safety of PrRingzaTM were demonstrated in two pivotal clinical studies of 13-cycle duration.BioSpaceDriven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in JapanMochida Pharmaceutical Co., Ltd. and Duchesnay Inc. have entered into a license agreement to bring Bonjesta®, a medication for nausea and vomiting of pregnancy, to the Japanese market. Mochida will conduct the necessary research to obtain regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency, with a target product launch by 2030. The agreement addresses Japan's "drug gap" issue, as Bonjesta® is approved in 43 countries but no similar medication is currently approved in Japan for this condition affecting over half of pregnant women.NewswireDriven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in JapanMochida Pharmaceutical Co., Ltd. and Duchesnay Inc. have entered into a license agreement to bring Bonjesta®, a medication for nausea and vomiting of pregnancy (NVP), to the Japanese market. Under the deal, Mochida will conduct the necessary research to obtain regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), with a potential product launch targeted for 2030. The partnership addresses a significant drug gap in Japan, where more than half of pregnant women experience NVP but no approved medications currently exist, despite Bonjesta® being available in 43 countries worldwide.NewswireAnalog Pharma Canada launches its first product on the Canadian marketAnalog Pharma Canada, a pharmaceutical company founded in January 2024 and part of Duchesnay Pharmaceutical Group (DPG), has launched its first product on the Canadian market: PrALOG-Doxylamine/PyridoxineTM, a generic version of DPG's flagship drug PrDiclectin® indicated for managing nausea and vomiting of pregnancy. The company highlighted that its Quebec-based manufacturing facilities ensure reliable product availability amid fluctuating geopolitical conditions. This launch marks Analog Pharma Canada's entry into the pharmaceutical market as it begins building a portfolio of high-quality, affordable generic medications targeting orphan drugs and Duchesnay-owned products.